Nikko Asset Management Americas, Inc. Rubius Therapeutics, Inc. Transaction History

Nikko Asset Management Americas, Inc.

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2020 Apr 30, 2020	SELL	$3.74 - $9.84 $5.37 Million - $14.1 Million	-1,436,013 Closed	0 $0
Q4 2019 Feb 06, 2020	SELL	$7.23 - $14.12 $150,593 - $294,105	-20,829 Reduced 1.43%	1,436,013 $13.6 Million
Q3 2019 Oct 29, 2019	BUY	$7.85 - $15.75 $1.59 Million - $3.19 Million	202,684 Added 16.16%	1,456,842 $11.4 Million
Q2 2019 Jul 29, 2019	BUY	$13.5 - $19.94 $9.94 Million - $14.7 Million	736,490 Added 142.27%	1,254,158 $19.7 Million
Q1 2019 Apr 30, 2019	BUY	$13.27 - $18.51 $6.87 Million - $9.58 Million	517,668 New	517,668 $9.37 Million

325

Ticker RUBY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 90,357,000
Description
Rubius Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of red cell therapeutics (RCTs) for the treatment of patients with severe diseases. The company is developing RTX-240 and RTX-224 for the treatment of solid tumors cancer; and RTX-aAPC to treat cancers. It is also developing RTX-321 for the treatmen...

Get notified when there are updates to the investment portfolio of Nikko Asset Management Americas, Inc., based on Form 13F filings with the SEC.

Stay updated on Nikko Asset Management Americas, Inc. with notifications on news.